1	Over	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	last	_	_	JJ	_	_	_	_	_
4	two	_	_	CD	_	_	_	_	_
5	decades	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	remarkable	_	_	JJ	_	_	_	_	_
8	progress	_	_	NN	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	been	_	_	VBN	_	_	_	_	_
11	made	_	_	VBN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	understanding	_	_	VBG	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	etiology	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	pathophysiology	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	diseases	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	New	_	_	JJ	_	_	_	_	_
2	discoveries	_	_	NNS	_	_	_	_	_
3	emphasize	_	_	VBP	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	importance	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	small	_	_	JJ	_	_	_	_	_
9	bowel	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	SB	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	‘	_	_	``	_	_	_	_	_
14	ecosystem	_	_	NN	_	_	_	_	_
15	’	_	_	''	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	pathogenesis	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	acute	_	_	JJ	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	chronic	_	_	JJ	_	_	_	_	_
23	illness	_	_	NN	_	_	_	_	_
24	alike	_	_	RB	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Emerging	_	_	VBG	_	_	_	_	_
2	factors	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	such	_	_	JJ	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	microbiome	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	stem	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	progenitor	_	_	NN	_	_	_	_	_
11	cells	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	innate	_	_	JJ	_	_	_	_	_
14	intestinal	_	_	JJ	_	_	_	_	_
15	immunity	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	enteric	_	_	JJ	_	_	_	_	_
20	nervous	_	_	JJ	_	_	_	_	_
21	system	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	along	_	_	IN	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	mucosal	_	_	JJ	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	endothelial	_	_	JJ	_	_	_	_	_
28	barriers	_	_	NNS	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	play	_	_	VB	_	_	_	_	_
31	a	_	_	DT	_	_	_	_	_
32	key	_	_	JJ	_	_	_	_	_
33	role	_	_	NN	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	development	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	gastrointestinal	_	_	JJ	_	_	_	_	_
39	(	_	_	-LRB-	_	_	_	_	_
40	GI	_	_	NN	_	_	_	_	_
41	)	_	_	-RRB-	_	_	_	_	_
42	and	_	_	CC	_	_	_	_	_
43	extra-GI	_	_	JJ	_	_	_	_	_
44	diseases	_	_	NNS	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	other	_	_	JJ	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	point	_	_	VBP	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	towards	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	link	_	_	NN	_	_	_	_	_
11	between	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	digestive	_	_	JJ	_	_	_	_	_
14	tract	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	common	_	_	JJ	_	_	_	_	_
17	non-communicable	_	_	JJ	_	_	_	_	_
18	diseases	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	such	_	_	JJ	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	obesity	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	cancer	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	discoveries	_	_	NNS	_	_	_	_	_
3	unravel	_	_	VBP	_	_	_	_	_
4	novel	_	_	JJ	_	_	_	_	_
5	dimensions	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	uncertainty	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	area	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	clinical	_	_	JJ	_	_	_	_	_
13	decision-making	_	_	NN	_	_	_	_	_
14	motivating	_	_	VBG	_	_	_	_	_
15	researchers	_	_	NNS	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	search	_	_	VB	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	novel	_	_	JJ	_	_	_	_	_
20	diagnostic	_	_	JJ	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	therapeutic	_	_	JJ	_	_	_	_	_
23	solutions	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Recent	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	unravel	_	_	VBP	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	role	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	poorly-understood	_	_	JJ	_	_	_	_	_
9	complexity	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	SB	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Insights	_	_	NNS	_	_	_	_	_
2	into	_	_	IN	_	_	_	_	_
3	its	_	_	PRP$	_	_	_	_	_
4	critical	_	_	JJ	_	_	_	_	_
5	physiologic	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	pathophysiologic	_	_	JJ	_	_	_	_	_
8	role	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	metabolic	_	_	JJ	_	_	_	_	_
11	homeostasis	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	its	_	_	PRP$	_	_	_	_	_
14	potential	_	_	JJ	_	_	_	_	_
15	role	_	_	NN	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	driver	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	obesity	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	insulin	_	_	NN	_	_	_	_	_
23	resistance	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	subsequent	_	_	JJ	_	_	_	_	_
27	type	_	_	NN	_	_	_	_	_
28	2	_	_	CD	_	_	_	_	_
29	diabetes	_	_	NNS	_	_	_	_	_
30	mellitus	_	_	NN	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	T2DM	_	_	NNP	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	have	_	_	VBP	_	_	_	_	_
35	been	_	_	VBN	_	_	_	_	_
36	revealed	_	_	VBN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	bypassing	_	_	VBG	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	proximal	_	_	JJ	_	_	_	_	_
7	small	_	_	JJ	_	_	_	_	_
8	intestine	_	_	NN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	means	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	bariatric	_	_	JJ	_	_	_	_	_
13	surgery	_	_	NN	_	_	_	_	_
14	results	_	_	VBZ	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	significant	_	_	JJ	_	_	_	_	_
18	metabolic	_	_	JJ	_	_	_	_	_
19	benefit	_	_	NN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	an	_	_	DT	_	_	_	_	_
22	individual	_	_	NN	_	_	_	_	_
23	undergoing	_	_	VBG	_	_	_	_	_
24	such	_	_	PDT	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	procedure	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	endoscopic	_	_	JJ	_	_	_	_	_
4	procedures	_	_	NNS	_	_	_	_	_
5	aimed	_	_	VBN	_	_	_	_	_
6	at	_	_	IN	_	_	_	_	_
7	placing	_	_	VBG	_	_	_	_	_
8	devices	_	_	NNS	_	_	_	_	_
9	separating	_	_	VBG	_	_	_	_	_
10	luminal	_	_	JJ	_	_	_	_	_
11	contents	_	_	NNS	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	duodenal	_	_	JJ	_	_	_	_	_
15	mucosa	_	_	NN	_	_	_	_	_
16	result	_	_	VBP	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	modest	_	_	JJ	_	_	_	_	_
19	weight	_	_	NN	_	_	_	_	_
20	loss	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	improvement	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	glucose	_	_	NN	_	_	_	_	_
25	homeostasis	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	endoscopic	_	_	JJ	_	_	_	_	_
3	treatment	_	_	NN	_	_	_	_	_
4	which	_	_	WDT	_	_	_	_	_
5	aims	_	_	VBZ	_	_	_	_	_
6	at	_	_	IN	_	_	_	_	_
7	resurfacing	_	_	VBG	_	_	_	_	_
8	duodenal	_	_	JJ	_	_	_	_	_
9	mucosa	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	DMR	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	duodenal	_	_	JJ	_	_	_	_	_
14	mucosal	_	_	JJ	_	_	_	_	_
15	resurfacing	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	leads	_	_	VBZ	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	improvement	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	glycemia	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	insulin	_	_	NN	_	_	_	_	_
25	resistance	_	_	NN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	patients	_	_	NNS	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	T2DM	_	_	NNP	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	surprising	_	_	JJ	_	_	_	_	_
5	when	_	_	WRB	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	recall	_	_	VBP	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	SB	_	_	NN	_	_	_	_	_
10	endocrine	_	_	NN	_	_	_	_	_
11	cells	_	_	NNS	_	_	_	_	_
12	secrete	_	_	VBP	_	_	_	_	_
13	glycemia-regulating	_	_	JJ	_	_	_	_	_
14	incretin	_	_	NN	_	_	_	_	_
15	hormones	_	_	NNS	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	e.	_	_	NN	_	_	_	_	_
18	g.	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	glucagon-like	_	_	JJ	_	_	_	_	_
21	peptide	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	GLP-1	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	this	_	_	DT	_	_	_	_	_
28	process	_	_	NN	_	_	_	_	_
29	is	_	_	VBZ	_	_	_	_	_
30	dependent	_	_	VBN	_	_	_	_	_
31	on	_	_	IN	_	_	_	_	_
32	food	_	_	NN	_	_	_	_	_
33	content	_	_	NN	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	intestinal	_	_	JJ	_	_	_	_	_
37	lumen	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	bile	_	_	NN	_	_	_	_	_
4	acids	_	_	NNS	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	various	_	_	JJ	_	_	_	_	_
7	targets	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	liver	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	small	_	_	JJ	_	_	_	_	_
13	intestine	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	e.	_	_	FW	_	_	_	_	_
16	g.	_	_	FW	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	farnesoid	_	_	NN	_	_	_	_	_
19	receptor	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	FXR	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	together	_	_	RB	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	plethora	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	other	_	_	JJ	_	_	_	_	_
29	small	_	_	JJ	_	_	_	_	_
30	signaling	_	_	NN	_	_	_	_	_
31	molecules	_	_	NNS	_	_	_	_	_
32	act	_	_	VB	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	concert	_	_	NN	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	regulating	_	_	VBG	_	_	_	_	_
37	metabolic	_	_	JJ	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	digestive	_	_	JJ	_	_	_	_	_
40	GI	_	_	NN	_	_	_	_	_
41	function	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	human	_	_	JJ	_	_	_	_	_
3	digestive	_	_	JJ	_	_	_	_	_
4	tract	_	_	NN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	enteric	_	_	JJ	_	_	_	_	_
7	nervous	_	_	JJ	_	_	_	_	_
8	system	_	_	NN	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	ENS	_	_	NNP	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	communicate	_	_	VBP	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	central	_	_	JJ	_	_	_	_	_
16	nervous	_	_	JJ	_	_	_	_	_
17	system	_	_	NN	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	CNS	_	_	NNP	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	through	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	gut-brain	_	_	NN	_	_	_	_	_
24	axis	_	_	NN	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	GBA	_	_	NNP	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	bidirectional	_	_	JJ	_	_	_	_	_
3	communication	_	_	NN	_	_	_	_	_
4	involves	_	_	VBZ	_	_	_	_	_
5	diverse	_	_	JJ	_	_	_	_	_
6	neural	_	_	JJ	_	_	_	_	_
7	networks	_	_	NNS	_	_	_	_	_
8	through	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	X	_	_	NN	_	_	_	_	_
11	cranial	_	_	JJ	_	_	_	_	_
12	vagal	_	_	JJ	_	_	_	_	_
13	nerve	_	_	NN	_	_	_	_	_
14	—	_	_	:	_	_	_	_	_
15	dorsal	_	_	JJ	_	_	_	_	_
16	roots	_	_	NNS	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	sympathetic/	_	_	JJ	_	_	_	_	_
20	parasympathetic	_	_	JJ	_	_	_	_	_
21	nervous	_	_	JJ	_	_	_	_	_
22	system	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Important	_	_	JJ	_	_	_	_	_
2	roles	_	_	NNS	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	regulation	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	gut-brain	_	_	NN	_	_	_	_	_
9	axis	_	_	NN	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	played	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	:	_	_	:	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	i	_	_	CD	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	hypothalamus-pituitary-adrenal	_	_	JJ	_	_	_	_	_
19	axis	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	HPA	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	ii	_	_	CD	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	stress	_	_	NN	_	_	_	_	_
29	hormones	_	_	NNS	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	cortisol	_	_	NN	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	(	_	_	-LRB-	_	_	_	_	_
35	iii	_	_	NN	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	short-chain	_	_	JJ	_	_	_	_	_
39	fatty	_	_	NN	_	_	_	_	_
40	acids	_	_	NNS	_	_	_	_	_
41	(	_	_	-LRB-	_	_	_	_	_
42	SCFAs	_	_	NNP	_	_	_	_	_
43	)	_	_	-RRB-	_	_	_	_	_
44	,	_	_	,	_	_	_	_	_
45	and	_	_	CC	_	_	_	_	_
46	(	_	_	-LRB-	_	_	_	_	_
47	iv	_	_	NN	_	_	_	_	_
48	)	_	_	-RRB-	_	_	_	_	_
49	the	_	_	DT	_	_	_	_	_
50	gut	_	_	NN	_	_	_	_	_
51	microbiota	_	_	NN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	intestinal	_	_	JJ	_	_	_	_	_
3	barrier	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	another	_	_	DT	_	_	_	_	_
6	important	_	_	JJ	_	_	_	_	_
7	part	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	GBA	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	composed	_	_	VBN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	:	_	_	:	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	i	_	_	CD	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	goblet	_	_	NN	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	derived	_	_	VBN	_	_	_	_	_
21	mucus	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	ii	_	_	FW	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	microbiota	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	iii	_	_	NN	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	epithelial	_	_	JJ	_	_	_	_	_
32	cells	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	(	_	_	-LRB-	_	_	_	_	_
35	iv	_	_	NN	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	endothelial	_	_	JJ	_	_	_	_	_
38	cells	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	v	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	lymphatic	_	_	JJ	_	_	_	_	_
44	vessels	_	_	NNS	_	_	_	_	_
45	,	_	_	,	_	_	_	_	_
46	and	_	_	CC	_	_	_	_	_
47	v	_	_	NN	_	_	_	_	_
48	)	_	_	-RRB-	_	_	_	_	_
49	enterocytes	_	_	NNS	_	_	_	_	_
50	’	_	_	POS	_	_	_	_	_
51	tight	_	_	JJ	_	_	_	_	_
52	cellular	_	_	JJ	_	_	_	_	_
53	junctions	_	_	NNS	_	_	_	_	_
54	.	_	_	.	_	_	_	_	_


1	Of	_	_	IN	_	_	_	_	_
2	interest	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	structure	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	function	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	intestinal	_	_	JJ	_	_	_	_	_
11	barrier	_	_	NN	_	_	_	_	_
12	resemble	_	_	VBP	_	_	_	_	_
13	that	_	_	DT	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	blood-brain	_	_	NN	_	_	_	_	_
17	barrier	_	_	NN	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	BBB	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	gut-brain	_	_	JJ	_	_	_	_	_
3	communication	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	mediated	_	_	VBN	_	_	_	_	_
6	via	_	_	IN	_	_	_	_	_
7	blood	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	portal/hepatic	_	_	JJ	_	_	_	_	_
10	circulation	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	bone	_	_	NN	_	_	_	_	_
15	marrow	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	described	_	_	VBN	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	alterations	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	intestinal	_	_	JJ	_	_	_	_	_
13	barrier	_	_	NN	_	_	_	_	_
14	play	_	_	VBP	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	crucial	_	_	JJ	_	_	_	_	_
17	role	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	pathology	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	several	_	_	JJ	_	_	_	_	_
23	human	_	_	JJ	_	_	_	_	_
24	inflammatory	_	_	JJ	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	autoimmune	_	_	JJ	_	_	_	_	_
27	diseases	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_
29	Mohanan	_	_	NNP	_	_	_	_	_
30	et	_	_	FW	_	_	_	_	_
31	al.	_	_	FW	_	_	_	_	_
32	documented	_	_	VBD	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	crucial	_	_	JJ	_	_	_	_	_
35	role	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	C1orf106	_	_	NNP	_	_	_	_	_
39	inflammatory	_	_	JJ	_	_	_	_	_
40	bowel	_	_	NN	_	_	_	_	_
41	disease	_	_	NN	_	_	_	_	_
42	(	_	_	-LRB-	_	_	_	_	_
43	IBD	_	_	NNP	_	_	_	_	_
44	)	_	_	-RRB-	_	_	_	_	_
45	susceptibility	_	_	NN	_	_	_	_	_
46	gene	_	_	NN	_	_	_	_	_
47	in	_	_	IN	_	_	_	_	_
48	stabilizing	_	_	VBG	_	_	_	_	_
49	intestinal	_	_	JJ	_	_	_	_	_
50	barrier	_	_	NN	_	_	_	_	_
51	function	_	_	NN	_	_	_	_	_
52	and	_	_	CC	_	_	_	_	_
53	intestinal	_	_	JJ	_	_	_	_	_
54	inflammation	_	_	NN	_	_	_	_	_
55	.	_	_	.	_	_	_	_	_
56	Manfredo	_	_	NNP	_	_	_	_	_
57	Vieira	_	_	NNP	_	_	_	_	_
58	et	_	_	FW	_	_	_	_	_
59	al.	_	_	FW	_	_	_	_	_
60	evidenced	_	_	VBD	_	_	_	_	_
61	the	_	_	DT	_	_	_	_	_
62	role	_	_	NN	_	_	_	_	_
63	of	_	_	IN	_	_	_	_	_
64	pathobionts	_	_	NNS	_	_	_	_	_
65	in	_	_	IN	_	_	_	_	_
66	the	_	_	DT	_	_	_	_	_
67	process	_	_	NN	_	_	_	_	_
68	of	_	_	IN	_	_	_	_	_
69	intestinal	_	_	JJ	_	_	_	_	_
70	barrier	_	_	NN	_	_	_	_	_
71	alterations	_	_	NNS	_	_	_	_	_
72	,	_	_	,	_	_	_	_	_
73	which	_	_	WDT	_	_	_	_	_
74	were	_	_	VBD	_	_	_	_	_
75	followed	_	_	VBN	_	_	_	_	_
76	by	_	_	IN	_	_	_	_	_
77	their	_	_	PRP$	_	_	_	_	_
78	translocation	_	_	NN	_	_	_	_	_
79	to	_	_	TO	_	_	_	_	_
80	lymph	_	_	NN	_	_	_	_	_
81	nodes	_	_	NNS	_	_	_	_	_
82	and	_	_	CC	_	_	_	_	_
83	the	_	_	DT	_	_	_	_	_
84	hepatic	_	_	JJ	_	_	_	_	_
85	portal	_	_	NN	_	_	_	_	_
86	system	_	_	NN	_	_	_	_	_
87	,	_	_	,	_	_	_	_	_
88	triggering	_	_	VBG	_	_	_	_	_
89	systemic	_	_	JJ	_	_	_	_	_
90	lupus	_	_	NN	_	_	_	_	_
91	erythematosus	_	_	NN	_	_	_	_	_
92	(	_	_	-LRB-	_	_	_	_	_
93	SLE	_	_	NNP	_	_	_	_	_
94	)	_	_	-RRB-	_	_	_	_	_
95	.	_	_	.	_	_	_	_	_
96	Thaiss	_	_	NNP	_	_	_	_	_
97	et	_	_	FW	_	_	_	_	_
98	al.	_	_	FW	_	_	_	_	_
99	reported	_	_	VBD	_	_	_	_	_
100	that	_	_	IN	_	_	_	_	_
101	hyperglycemia	_	_	NN	_	_	_	_	_
102	leads	_	_	VBZ	_	_	_	_	_
103	to	_	_	TO	_	_	_	_	_
104	disruption	_	_	NN	_	_	_	_	_
105	of	_	_	IN	_	_	_	_	_
106	the	_	_	DT	_	_	_	_	_
107	intestinal	_	_	JJ	_	_	_	_	_
108	barrier	_	_	NN	_	_	_	_	_
109	followed	_	_	VBN	_	_	_	_	_
110	by	_	_	IN	_	_	_	_	_
111	intestinal	_	_	JJ	_	_	_	_	_
112	inflammation	_	_	NN	_	_	_	_	_
113	and	_	_	CC	_	_	_	_	_
114	systemic	_	_	JJ	_	_	_	_	_
115	infection	_	_	NN	_	_	_	_	_
116	.	_	_	.	_	_	_	_	_
117	Spadoni	_	_	NNP	_	_	_	_	_
118	et	_	_	FW	_	_	_	_	_
119	al.	_	_	FW	_	_	_	_	_
120	recently	_	_	RB	_	_	_	_	_
121	documented	_	_	VBD	_	_	_	_	_
122	that	_	_	IN	_	_	_	_	_
123	the	_	_	DT	_	_	_	_	_
124	presence	_	_	NN	_	_	_	_	_
125	of	_	_	IN	_	_	_	_	_
126	the	_	_	DT	_	_	_	_	_
127	gut-vascular	_	_	JJ	_	_	_	_	_
128	barrier	_	_	NN	_	_	_	_	_
129	(	_	_	-LRB-	_	_	_	_	_
130	GVB	_	_	NNP	_	_	_	_	_
131	)	_	_	-RRB-	_	_	_	_	_
132	in	_	_	IN	_	_	_	_	_
133	the	_	_	DT	_	_	_	_	_
134	small	_	_	JJ	_	_	_	_	_
135	intestine	_	_	NN	_	_	_	_	_
136	controls	_	_	VBZ	_	_	_	_	_
137	the	_	_	DT	_	_	_	_	_
138	dissemination	_	_	NN	_	_	_	_	_
139	of	_	_	IN	_	_	_	_	_
140	bacteria	_	_	NN	_	_	_	_	_
141	into	_	_	IN	_	_	_	_	_
142	the	_	_	DT	_	_	_	_	_
143	bloodstream	_	_	NN	_	_	_	_	_
144	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	authors	_	_	NNS	_	_	_	_	_
3	reported	_	_	VBD	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	decrease	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	wnt/beta	_	_	NN	_	_	_	_	_
9	catenin-inducible	_	_	JJ	_	_	_	_	_
10	gene	_	_	NN	_	_	_	_	_
11	Axin2	_	_	NNP	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	marker	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	stem	_	_	NN	_	_	_	_	_
17	cell	_	_	NN	_	_	_	_	_
18	renewal	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	gut	_	_	NN	_	_	_	_	_
22	endothelium	_	_	NN	_	_	_	_	_
23	under	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	presence	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	Salmonella	_	_	NNP	_	_	_	_	_
28	typhimirum	_	_	NN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	SB	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	GVB	_	_	NNP	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	modified	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	coeliac	_	_	NN	_	_	_	_	_
9	disease	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	CD	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	altered	_	_	VBN	_	_	_	_	_
15	serum	_	_	NN	_	_	_	_	_
16	transaminases	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	which	_	_	WDT	_	_	_	_	_
19	suggests	_	_	VBZ	_	_	_	_	_
20	that	_	_	IN	_	_	_	_	_
21	GVB	_	_	NN	_	_	_	_	_
22	deterioration	_	_	NN	_	_	_	_	_
23	may	_	_	MD	_	_	_	_	_
24	be	_	_	VB	_	_	_	_	_
25	responsible	_	_	JJ	_	_	_	_	_
26	for	_	_	IN	_	_	_	_	_
27	liver	_	_	NN	_	_	_	_	_
28	damage	_	_	NN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	CD	_	_	NN	_	_	_	_	_
31	patients	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	disruption	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	epithelial	_	_	JJ	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	vascular	_	_	JJ	_	_	_	_	_
11	barriers	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	intestine	_	_	NN	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	early	_	_	JJ	_	_	_	_	_
17	events	_	_	NNS	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	non-alcoholic	_	_	JJ	_	_	_	_	_
20	steatohepatitis	_	_	NN	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	NASH	_	_	NNP	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	GVB	_	_	NN	_	_	_	_	_
27	leakage	_	_	NN	_	_	_	_	_
28	marker	_	_	NN	_	_	_	_	_
29	could	_	_	MD	_	_	_	_	_
30	be	_	_	VB	_	_	_	_	_
31	identified	_	_	VBN	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	colonic	_	_	JJ	_	_	_	_	_
34	biopsies	_	_	NNS	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	patients	_	_	NNS	_	_	_	_	_
37	with	_	_	IN	_	_	_	_	_
38	NASH	_	_	NNP	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Of	_	_	IN	_	_	_	_	_
2	importance	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	SB	_	_	NN	_	_	_	_	_
5	epithelial	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	vascular	_	_	JJ	_	_	_	_	_
8	barriers	_	_	NNS	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	FXR-controlled	_	_	JJ	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	which	_	_	WDT	_	_	_	_	_
13	opens	_	_	VBZ	_	_	_	_	_
14	avenues	_	_	NNS	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	clinical	_	_	JJ	_	_	_	_	_
17	trials	_	_	NNS	_	_	_	_	_
18	aimed	_	_	VBN	_	_	_	_	_
19	at	_	_	IN	_	_	_	_	_
20	investigation	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	novel	_	_	JJ	_	_	_	_	_
23	FXR-agonists	_	_	NNPS	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	future	_	_	JJ	_	_	_	_	_
26	therapeutics	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Of	_	_	IN	_	_	_	_	_
2	interest	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	intestinal	_	_	JJ	_	_	_	_	_
5	barriers	_	_	NNS	_	_	_	_	_
6	could	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	monitored	_	_	VBN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	vivo	_	_	NN	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	aid	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	confocal	_	_	JJ	_	_	_	_	_
16	laser	_	_	NN	_	_	_	_	_
17	endomicroscopy	_	_	NN	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	CLE	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	SB	_	_	NNP	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	considered	_	_	VBN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	key	_	_	JJ	_	_	_	_	_
9	player	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	metabolic	_	_	JJ	_	_	_	_	_
12	disease	_	_	NN	_	_	_	_	_
13	development	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	including	_	_	VBG	_	_	_	_	_
16	diabetes	_	_	NN	_	_	_	_	_
17	mellitus	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	NASH	_	_	NNP	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	other	_	_	JJ	_	_	_	_	_
23	diet-related	_	_	JJ	_	_	_	_	_
24	disorders	_	_	NNS	_	_	_	_	_
25	such	_	_	JJ	_	_	_	_	_
26	as	_	_	IN	_	_	_	_	_
27	coeliac	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	non-coeliac	_	_	JJ	_	_	_	_	_
30	enteropathies	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	major	_	_	JJ	_	_	_	_	_
3	field	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	drug	_	_	NN	_	_	_	_	_
6	metabolism	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	its	_	_	PRP$	_	_	_	_	_
9	interaction	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	small	_	_	JJ	_	_	_	_	_
12	bowel	_	_	NN	_	_	_	_	_
13	microbiome	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	emergence	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	gut-brain	_	_	JJ	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	gut-liver	_	_	JJ	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	gut-blood	_	_	JJ	_	_	_	_	_
12	barriers	_	_	NNS	_	_	_	_	_
13	point	_	_	VBP	_	_	_	_	_
14	towards	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	important	_	_	JJ	_	_	_	_	_
17	role	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	SB	_	_	NNP	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	pathogenesis	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	previously	_	_	RB	_	_	_	_	_
26	unthought	_	_	JJ	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	GI-unrelated	_	_	JJ	_	_	_	_	_
29	conditions	_	_	NNS	_	_	_	_	_
30	such	_	_	JJ	_	_	_	_	_
31	as	_	_	IN	_	_	_	_	_
32	neurodegenerative	_	_	JJ	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	cardiovascular	_	_	JJ	_	_	_	_	_
35	disease	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	SB	_	_	NNP	_	_	_	_	_
3	remains	_	_	VBZ	_	_	_	_	_
4	an	_	_	DT	_	_	_	_	_
5	organ	_	_	NN	_	_	_	_	_
6	that	_	_	WDT	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	difficult	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	fully	_	_	RB	_	_	_	_	_
11	access	_	_	VB	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	assess	_	_	VB	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	accurate	_	_	JJ	_	_	_	_	_
16	diagnosis	_	_	NN	_	_	_	_	_
17	often	_	_	RB	_	_	_	_	_
18	poses	_	_	VBZ	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	clinical	_	_	JJ	_	_	_	_	_
21	challenge	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Undoubtedly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	therapeutic	_	_	JJ	_	_	_	_	_
5	potential	_	_	NN	_	_	_	_	_
6	remains	_	_	VBZ	_	_	_	_	_
7	untapped	_	_	JJ	_	_	_	_	_
8	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	now	_	_	RB	_	_	_	_	_
6	time	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	direct	_	_	VB	_	_	_	_	_
9	more	_	_	JJR	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	our	_	_	PRP$	_	_	_	_	_
12	interest	_	_	NN	_	_	_	_	_
13	towards	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	SB	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	unravel	_	_	VB	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	interplay	_	_	NN	_	_	_	_	_
20	between	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	SB	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	other	_	_	JJ	_	_	_	_	_
25	GI	_	_	NNP	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	non-GI	_	_	JJ	_	_	_	_	_
28	related	_	_	JJ	_	_	_	_	_
29	diseases	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_

